Vildagliptin: the first innovative DDP-4 inhibitor

Abstract

A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity of the action of this molecule are presentedalong with the results of its comparison with another agent of this group (sitagliptin).

Keywords

• dipeptidyl peptidase-4 inhibitor
• dpp-4
• vildagliptin
• novartis